PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty?
about
sameAs
Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists--in vitro experienceA critical appraisal of the phenomenon of aspirin resistancePlatelet activation, myocardial ischemic events and postoperative non-response to aspirin in patients undergoing major vascular surgeryDo the Behring Coagulation Timer and the Platelet Function Analyzer-100 identify the same patients as being aspirin non-responders?Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood.Aspirin resistance: Fact or fiction? A point of view.The platelet-function analyzer (PFA-100) for evaluating primary hemostasis.Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence.Effect of cocoa products and flavanols on platelet aggregation in humans: a systematic review.Clopidogrel resistance: fact and fiction.Monitoring aspirin therapy with the Platelet Function Analyzer-100.In vitro effects of gelatin solutions on platelet function: a comparison with hydroxyethyl starch solutions.Utility of PFA-100 closure time vs. optical aggregometry in assessing the efficacy of platelet membrane glycoprotein IIb/IIIa antagonists in vitro.Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100).
P2860
Q28168089-D6ED20DD-8F3B-409F-BF1E-A638C549AF63Q28183919-2E930860-A5E7-4425-8B33-22AE10A72E94Q28218788-99B68289-F17A-4865-834D-07E6C195C8BAQ28218887-3B990609-9A7A-4F49-A4BB-4B95C0DBC0D8Q30498026-F74ED502-8F07-4D16-8C0E-2BB3CFF92266Q34389630-1B817B5B-2220-4C3E-9C64-9C8FA324DD89Q36194570-59DC7B03-3045-4791-AB77-CDB345C8DA7EQ37608580-BE296E29-F6F5-4EC4-9D7D-78A1752901F3Q38514821-D1193520-3E9E-4997-B7DB-C1F0BCFEF4ECQ40347840-7856FB96-43DA-4A77-B39E-BE79EC35A5FEQ46465847-7B0CBCAD-FA1F-4016-A13A-48EC5D1217B6Q46512084-1AA32EF4-EB25-414F-860C-E9880E9B217CQ46923683-CFD4D72D-EB5F-4448-9043-2ACE126681C8Q50676873-47278874-C468-4F12-B8DF-B685D351DF9D
P2860
PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty?
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
PFA-100 and flow cytometry: ca ...... kers, in coronary angioplasty?
@ast
PFA-100 and flow cytometry: ca ...... kers, in coronary angioplasty?
@en
PFA-100 and flow cytometry: ca ...... kers, in coronary angioplasty?
@nl
type
label
PFA-100 and flow cytometry: ca ...... kers, in coronary angioplasty?
@ast
PFA-100 and flow cytometry: ca ...... kers, in coronary angioplasty?
@en
PFA-100 and flow cytometry: ca ...... kers, in coronary angioplasty?
@nl
prefLabel
PFA-100 and flow cytometry: ca ...... kers, in coronary angioplasty?
@ast
PFA-100 and flow cytometry: ca ...... kers, in coronary angioplasty?
@en
PFA-100 and flow cytometry: ca ...... kers, in coronary angioplasty?
@nl
P2093
P1433
P1476
PFA-100 and flow cytometry: ca ...... kers, in coronary angioplasty?
@en
P2093
Chantal Droullé
Damien Metz
Gérard Potron
Nathalie Hézard
Philippe Nguyen
Pierre Nazeyrollas
P356
10.1016/S0049-3848(02)00391-2
P407
P577
2002-10-01T00:00:00Z